Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEMOMAR: Maraviroc and Chemotherapy for HIV-1 Eradication
NCT02486510Phase 1Terminated
- Start
- Jul 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maraviroc in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoint: Number of resting memory CD4+ T cells latently infected with replicative HIV-1 at 6 months. Started Jul 2012; status: terminated.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02486510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486510.